Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASKG315 |
| Synonyms | |
| Therapy Description |
ASKG315 is an IL-15 prodrug that potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASKG315 | ASKG-315|ASKG 315|ASKG215b|ASKG215beta|ASKG 215b | ASKG315 is an IL-15 prodrug that potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05509985 | Phase I | ASKG315 | A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors | Unknown status | AUS | 0 |